Industry Awardees 2012

PhRMA Industry Awardees

MERCK BACE TEAM:

Eric M. Parker, Ph.D.
Executive Director and Neuroscience Site Lead
Merck Research Laboratories
Kenilworth, New Jersey

Dr. Eric M. Parker joined Merck Research Laboratories (MRL; formerly the Schering-Plough Research Institute) in Kenilworth, NJ in 1996 and is currently Executive Director and Neuroscience Site Lead.  In his present role, he oversees research aimed at developing novel treatments for Alzheimer’s disease and Parkinson’s disease.  Dr. Parker has previously led drug discovery efforts aimed at the treatment of obesity and metabolic disease, psychiatric disease, and nausea and vomiting.  In addition to his drug discovery responsibilities, Dr. Parker has also led four development teams during his tenure at MRL. In 2011, Dr. Parker was chosen to be a Merck Presidential Fellow by Dr. Peter Kim, President of MRL.

Prior to joining Merck, Dr. Parker was a research scientist in Neuroscience Drug Discovery at Bristol-Myers Squibb Co. in Wallingford, CT from 1991-1996.  While at Bristol-Myers Squibb, Dr. Parker’s drug discovery efforts were focused in the areas of obesity, sleep disorders and anxiety/depression.

Dr. Parker has published more than 80 scientific articles, reviews and book chapters.  He has also lectured extensively at many scientific conferences, universities and companies.

Dr. Parker received his B.S. degree in pharmacy and his Ph.D. degree in pharmacology from the University of North Carolina at Chapel Hill and has been recognized as a Distinguished Alumnus of that institution.  He completed postdoctoral training at the University of Texas Southwestern Medical Center in Dallas.  Dr. Parker has been married for 26 years to Victoria Meadows Parker and has three children.  He enjoys backpacking, jogging, music, and military history.

Back to the Awards page

 

Andrew Stamford, Ph.D.
Executive Director of Medicinal Chemistry
Merck Research Laboratories
Rahway, New Jersey

Andrew Stamford is a 2012 Industry Award WinnerDr. Andrew Stamford is currently Executive Director of Medicinal Chemistry at Merck Research Laboratories, Rahway, NJ.  Prior to his current appointment, Dr. Stamford was a Director of Medicinal Chemistry at Schering Plough Research Institute where, after joining in 1991, he attained positions of increasing responsibility.

While at Schering-Plough and Merck, Dr. Stamford has contributed to or led drug discovery programs targeting enzyme inhibitors and G-protein coupled receptor agonists and antagonists as novel therapeutic agents for CNS and CV disorders, diabetes and infectious diseases.  From 2001-2011 Dr. Stamford was co-leader of the Merck/Schering-Plough BACE Inhibitor Discovery Team that discovered MK-8931, which is currently in clinical development for the treatment of Alzheimer's disease.

Dr. Stamford received his academic training in Australia, earning a BSc. (Hons) in Chemistry from the University of Tasmania in 1984, and a PhD in Organic Chemistry from the University of Sydney in 1989.  Following completion of his PhD, he was a Postdoctoral Fellow at the University of Texas at Austin engaged in natural products total synthesis.

Recognition that Dr. Stamford has received for his work includes the 2006 Schering-Plough President's Award for Discovery and the 2010 American Chemical Society David W. Robertson Award for Excellence in Medicinal Chemistry.  He is co-inventor of more than 40 issued United States Patents and co-author of over 50 publications.

Back to the Awards page

 

Dr. Matthew E. Kennedy, Ph.D.
Director
Neurosciences and Ophthalmology
Merck Research Laboratories

Dr. Kennedy is a pharmacologist focused on the discovery of disease modifying therapies for Alzheimer's disease (AD).  He joined the department of CNS Research at the Schering-Plough Research Institute in 1999 as a Senior Scientist an initially focused on neuroinflammation. In 2000, he began work on the discovery of BACE inhibitors as amyloid lowering agents for AD and continues as the BACE inhibitor program biology team lead.  Dr. Kennedy serves on the BACE clinical development team and also manages a team of scientists pursuing disease modifying therapies for Parkinson's disease.  In 2006, he received the Schering Plough President's Award for Discovery.

Prior to joining Merck, Dr. Kennedy studied the molecular basis of G-protein-gated ion channel assembly and function as a post doctoral fellow of the Howard Hughes Medical Institute at Boston Children's Hospital and the Mayo Clinic. 

Dr. Kennedy earned his undergraduate degree at Villanova University with honors in biology.  He received his Ph.D. in pharmacology from Vanderbilt University studying the impact of post-translational lipid modifications on the function of G-protein coupled receptors. 

Back to the Awards page

 

Mark S Forman, MD, PhD
Senior Principal Scientist
Merck Research Laboratories 

Mark Forman is a 2012 Industry Award WinnerMark Forman is a neuropathologist and biochemist whose resea rch has focused on the pathogenesis and treatment of neurodegenerative disease.

Dr. Forman is a Senior Principal Scientist in the Department of Clinical Pharmacology at Merck.  Dr. Forman joined Merck in 2007 where his work focuses on early clinical drug development, primarily in the therapeutic areas of Neurology and Psychiatry.  

Prior to joining Merck, Dr. Forman was an Assistant Professor of Pathology at the University of Pennsylvania where his research focused on the pathogenesis of neurodegenerative disease, including Alzheimer's disease, Parkinson's disease and Frontotemporal Dementia.  At the University of Pennsylvania, Dr. Forman was Director of the Brain Bank in the Center for Neurodegenerative Disease Research and Director of the Neuropathology Core of the Alzheimer's Disease Center. 

Dr. Forman received his undergraduate education at Yale University with a focus in Molecular Biophysics and Biochemistry.  He received his PhD in Immunology at Rockefeller University and his MD at Duke University.  He completed residency training in Anatomic Pathology and fellowship training in Neuropathology at the University of Pennsylvania.  He also completed postdoctoral training in the Center for Neurodegenerative Disease Research at the University of Pennsylvania with Drs. Virginia Lee and John Trojanowski. 

Dr. Forman is the author of more than 70 publications.  His work has earned him several awards including the 2003 Experimental Pathologist in Training Award. 

Back to the Awards page

 

Julie A. Stone, Ph.D.
Distinguished Scientist
Modeling and Simulation
Merck Research Laboratories

Dr. Stone joined Merck Research Laboratories (MRL) in 1995 and is currently responsible for scientific oversight of modeling and simulation in MRL's discovery and development programs.   She leads Merck's efforts in modeling of the disease process and pharmacology of therapeutic intervention in Alzheimer’s Disease and osteoporosis.

In her 17 years at Merck, Dr. Stone has contributed modeling and simulation, pharmacokinetics, and clinical pharmacology support for a variety of programs, including CANCIDAS™ (caspofungin), CRIXIVAN™ (indinavir), and PROPECIA™ (finasteride), IVEMEND™ (fosaprepitant), JANUVIA™ (sitagliptin), TREDAPTIVE™ (laropiprant/niacin), ISENTRESS™ (raltegravir), and VICTRELIS™ (boceprevir).

Dr. Stone received her undergraduate education at Union College, graduating summa cum laude with degrees in biology and mechanical engineering.  She received her M.S. and Ph.D. in bioengineering from the University of Pennsylvania and conducted postdoctoral research in pharmacokinetic modeling at Hoffmann-La Roche in Basel, Switzerland.

Awards received by Dr. Stone include the National Science Foundation Graduate Fellowship and the MRL Presidential Fellowship in recognition of her sustained record of superior scientific and technical impact to Merck research.

Back to the Awards page

More On PhRMA — powered by PhRMApedia